Travere Therapeutics Inc. (TVTX)
NASDAQ
50.49
+0.89 (+1.79%)
Closed
Oct 19, 2026
Day's Range
49.7451.28
52 wk Range
22.5968.73
Financial Statements - TVTX - Travere Therapeutics Inc.
Revenue
490.72M▲ 110.5%
Net Income
-25.54M▲ 92.1%Net Margin -5.2%
EBITDA
22.21M▲ 108.4%
Free Cash Flow
-20.37M▲ 94.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 490.72M | 233.17M | 145.23M | 109.46M | 131.83M | 198.32M |
| Cost of Goods | 10.33M | 7.74M | 11.45M | 4.42M | 3.81M | 6.12M |
| Gross Profit | 480.38M | 225.43M | 133.78M | 105.04M | 128.01M | 192.19M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -62.82M | -321.38M | -376.74M | -319.81M | -199.42M | -75.37M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 11.57M | -5.75M | -9.80M | -6.60M | 231K | -99.36M |
| Pre Tax Income | -49.27M | -320.51M | -376.11M | -331.15M | -216.88M | -188.79M |
| Income Tax | 988K | 120K | 223K | 313K | 409K | -19.35M |
| Net Income | -25.54M | -321.54M | -111.39M | -278.48M | -180.09M | -169.43M |
| EPS Basic | -0.29 | -4.08 | -1.5 | -4.37 | -3.01 | -3.56 |
| EPS Diluted | -0.29 | -4.08 | -1.5 | -4.37 | -3.01 | -3.56 |
| Basic Shares Outstanding | 89.21M | 78.88M | 74.26M | 63.75M | 59.83M | 47.53M |
| Diluted Shares Outstanding | 89.21M | 78.88M | 74.26M | 63.75M | 59.83M | 47.53M |
| Ebit | -38.52M | -309.32M | -364.77M | -320.14M | -197.20M | -169.74M |
| Ebitda | 22.21M | -263.33M | -314.85M | -291.84M | -184.45M | -44.37M |
| Net Income Continuous Operations | -50.26M | -320.63M | -376.33M | -331.46M | -217.29M | -169.43M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
